| 1 |
史 辉，齐燕辉. 创伤性心包积血伴类白血病反应一例[J]. 临床内科杂志，2016, 33(3): 207.
|
| 2 |
赵长明，谭 程，孙小康，等. 胸部恶性肿瘤病人类白血病反应的临床疗效分析[J]. 现代肿瘤医学，2012, 20(3): 538-540.
|
| 3 |
叶爱琴. 恶性肿瘤合并类白血病反应46例临床报告并肿瘤分期探讨[J]. 实用临床医药杂志，2014, 18(24): 123-124.
|
| 4 |
Granger JM, Kontoyiannis DP. Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study[J]. Cancer, 2009, 115(17): 3919-3923.
|
| 5 |
林梅英. 恶性肿瘤出现类白血病反应23例临床报告[J]. 临床误诊误治，2008, 21(7): 32-34.
|
| 6 |
付尚志，吴 雷，李万平. 恶性肿瘤类白血病反应14例临床分析[J]. 临床军医杂志，2009, 37(6): 1141-1142.
|
| 7 |
张新华，熊金元. 类白血病反应误诊分析[J]. 临床误诊误治，1997, 6: 337.
|
| 8 |
王柳倩，马 为. 肺癌并类白血病反应二例[J]. 临床内科杂志，2016, 33(11): 786-787.
|
| 9 |
夏淑兰，陈 平，黄信刚，等. 肺鳞癌并发嗜酸粒细胞型类白血病反应1例并文献复习[J]. 国际呼吸杂志，2013, 33(18): 1374-1379.
|
| 10 |
Song Z, Su H, Zhang Y. Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy[J]. Cancer Med, 2016, 5(10): 2688-2693.
|
| 11 |
李 博，邱彩霞，李万乐，等. 羟基脲介导的细胞周期同步化在外周血淋巴细胞高分辨染色体制片中的应用研究[J]. 中国保健营养，2017, 27(22): 148.
|
| 12 |
倪世杰. 慢性粒细胞白血病低危组应用羟基脲加干扰素α-2b治疗的观察[J]. 养生保健指南，2020, 48 (11): 61.
|
| 13 |
张红军，房延凤，苏 尉，等. 癌胚抗原对肺癌患者基因突变状况的预测价值[J]. 肿瘤药学，2017, 7(5): 545-550.
|
| 14 |
Yang JC, Schuler M, Popat S, et al. Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases[J]. J Thorac Oncol, 2020, 15(5): 803-815.
|
| 15 |
Okumoto J, Sakamoto S, Masuda T, et al. Alectinib-induced immune hemolytic anemia in a patient with lung adenocarcinoma[J]. Intern Med, 2021, 60(4): 611-615.
|
| 16 |
Stork L, Bruck W, von Gottberg P, et al. Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis[J]. Mult Scler, 2019, 25(12): 1618-1632.
|
| 17 |
Bielekova B. Daclizumab therapy for multiple sclerosis[J]. Cold Spring Harb Perspect Med, 2019, 9(5): 55-67.
|
| 18 |
Bianchi A, Ciccarelli O. Daclizumab-induced encephalitis in multiple sclerosis[J]. Mult Scler, 2019, 25(12): 1557-1559.
|
| 19 |
Chen YF, Hsieh MS, Wu SG, et al. Efficacy of pemetrexed-based chemotherapy in patients with ROS1 fusion-positive lung adenocarcinoma compared with in patients harboring other driver mutations in east asian populations[J]. J Thorac Oncol, 2016, 11(7): 1140-1152.
|
| 20 |
Shen L, Qiang T, Li Z, et al. First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer[J]. Cancer Med, 2020, 9(10): 3310-3318.
|
| 21 |
Butler SS, Muralidhar V, Zhao SG, et al. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012[J]. Cancer, 2020, 126(4): 717-724.
|
| 22 |
Kodama T, Tsukaguchi T, Satoh Y, et al. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer[J]. Mol Cancer Ther, 2014, 13(12): 2910-2918.
|